Durability of Response to Abrocitinib in Patients with Moderate-to-Severe Atopic Dermatitis After Treatment Discontinuation in a Phase 2b Trial

INTRODUCTION: Multiple clinical trials showed that 12 weeks of abrocitinib monotherapy was safe and effective for the treatment of moderate-to-severe atopic dermatitis (AD). The reversibility of pharmacologic activity after abrocitinib discontinuation was not described. METHODS: This post hoc analys...

Descripción completa

Detalles Bibliográficos
Autores principales: Gooderham, Melinda J., Girolomoni, Giampiero, Moore, Julian O., Silverberg, Jonathan I., Bissonnette, Robert, Forman, Seth, Peeva, Elena, Biswas, Pinaki, Valdez, Hernan, Chan, Gary
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464275/
https://www.ncbi.nlm.nih.gov/pubmed/35933552
http://dx.doi.org/10.1007/s13555-022-00764-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464275/
https://www.ncbi.nlm.nih.gov/pubmed/35933552
http://dx.doi.org/10.1007/s13555-022-00764-4

Ejemplares similares